What is Sangon Biotech?
Founded in 2003 and headquartered in Shanghai, Sangon Biotech has established itself as a critical infrastructure provider within the life sciences ecosystem. The company distinguishes itself through a vertically integrated business model, acting as an original manufacturer that maintains strict quality control across a vast portfolio of products. By focusing on competitive pricing and continuous R&D, Sangon Biotech has successfully captured significant market share, serving a diverse international clientele. Its operational philosophy centers on providing a seamless, end-to-end experience for researchers, effectively bridging the gap between complex laboratory requirements and high-quality, scalable supply chain solutions.
How much funding has Sangon Biotech raised?
Sangon Biotech has raised a total of $290M across 1 funding round:
Other Financing Round
$290M
Other Financing Round (2023): $290M with participation from Huagai Capital, CDB Venture, Novo Holdings, GL Capital, and Greenwoods Asset Management
Key Investors in Sangon Biotech
Huagai Capital
Huagai Capital is a professional investment firm operating within the investment banking sector, focused on identifying and scaling high-potential enterprises.
Novo Holdings
Novo Holdings is a Danish private limited liability company wholly owned by the Novo Nordisk Foundation, specializing in long-term life science investments.
GL Capital
GL Capital Ltd provides expert strategic business development and corporate finance advice, acting as a key partner for SMEs and startups seeking growth.
What's next for Sangon Biotech?
With the successful closure of this major strategic investment, Sangon Biotech is poised to enter a new phase of enterprise-level scaling. The company is expected to prioritize the expansion of its R&D facilities to foster further innovation in life science technologies. Furthermore, the capital will likely be deployed to enhance global distribution networks, ensuring that its comprehensive product catalog remains accessible to emerging markets. As the firm continues to pursue its goal of becoming a global leader, the focus will remain on maintaining the rigorous quality standards that have defined its growth to date, while simultaneously exploring new avenues for technological integration and service diversification.
See full Sangon Biotech company page
